Core Insights - Viz.ai has launched a new real-time clinical intelligence service for Salesforce's Agentforce Life Sciences, integrating data from nearly 2,000 hospitals covering 230 million lives in the U.S. [1] - The collaboration aims to streamline patient journeys and enhance clinician education by providing timely, actionable insights at the point of care [2][3]. Group 1: Service Features - The new service enables intelligent, closed-loop workflows that guide actions across commercial, medical, and patient support teams [2]. - It addresses challenges in the life sciences sector by unifying clinical and customer contexts, closing information gaps, and coordinating teams effectively [3]. - The Agentforce Life Sciences platform includes a library of ready-to-use skills, allowing for customization and extension of agent capabilities [4]. Group 2: Market Impact - The partnership between Viz.ai and Salesforce is positioned to transform the pharmaceutical go-to-market strategy into a continuous, point-of-care operating system [5]. - Over the past year, more than 110 life science companies have adopted Agentforce Life Sciences, indicating strong market interest and potential for growth [4]. - The integration of Viz.ai's real-time clinical signals with Agentforce Life Sciences aims to improve clinician engagement and patient onboarding processes [6]. Group 3: Company Background - Viz.ai is recognized as a leader in AI-powered care coordination and clinical workflow solutions, trusted by top life sciences companies and deployed in nearly 2,000 hospitals across the U.S. [8]. - The company has been awarded CMS reimbursement for its AI solutions and has been ranked as the 1 Healthcare AI Platform by hospitals and health systems [8].

Core Insights - Salesforce, Inc. (NYSE:CRM) is recognized as one of the best quality stocks to buy before 2026, particularly following its announcement of a partnership with Novartis to enhance customer engagement in the healthcare sector [1] Group 1: Partnership and Investment - Novartis has previously invested in Salesforce through various platforms including Agentforce Health and MuleSoft for Life Sciences, and now aims to unify engagement across multiple teams over the next five years [2] - The partnership will involve the global deployment of Agentforce 360 for Life Sciences, indicating a significant commitment to integrating Salesforce's technology within Novartis [2] Group 2: Market Sentiment and Analyst Ratings - Wall Street analysts are optimistic about Salesforce, with BTIG's Allan Verkhovski initiating coverage with a Buy rating and a price target of $335, while Mizuho Securities' Gregg Moskowitz reiterated a Buy rating with a $340 price target [3] - Analyst Verkhovski appreciates the re-architecture of Salesforce's core platform and notes management's confidence in accelerating net new annual order value, projecting a return to double-digit subscription revenue growth by fiscal Q4 2027 [4]

Core Insights - Salesforce, Inc. (NYSE:CRM) is recognized as one of the best quality stocks to buy before 2026, particularly following its announcement of a partnership with Novartis to enhance customer engagement in the healthcare sector [1] Group 1: Partnership and Investment - Novartis has previously invested in Salesforce through various platforms including Agentforce Health and MuleSoft for Life Sciences, and now aims to unify engagement across multiple teams over the next five years [2] - The partnership will involve the global deployment of Agentforce 360 for Life Sciences, indicating a significant commitment to integrating Salesforce's technology within Novartis [2] Group 2: Market Sentiment and Analyst Ratings - Wall Street analysts are optimistic about Salesforce, with BTIG's Allan Verkhovski initiating coverage with a Buy rating and a price target of $335, while Mizuho Securities' Gregg Moskowitz reiterated a Buy rating with a $340 price target [3] - Analyst Verkhovski appreciates Salesforce's re-architecture of its core platform and anticipates that the company's net new annual order value will accelerate, leading to a return to double-digit subscription revenue growth by fiscal Q4 2027 [4]